Patients with many hematologic tumors, including AML, have expression of LCN2 (Bouchet and Bauvois, 2014; Candido et al., 2014), which is required for the BCR-ABL-induced mouse leukemia model and is involved in damaging normal hematopoietic cells and inducing tissue invasion by leukemia cells (Leng et al., 2008). Here, ABL1 is linked to leukemia.